Conv. Plasma
Nigella Sativa

All vitamin C studies
Meta analysis
study COVID-19 treatment researchVitamin CVitamin C (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Death/intubation 25% primary Improvement Relative Risk ARDS 73% Vitamin C for COVID-19  Tan et al.  LATE TREATMENT Is late treatment with vitamin C + combined treatments beneficial for COVID-19? Retrospective 161 patients in China Lower progression with vitamin C + combined treatments (p=0.002) Tan et al., QJM, July 2021 Favors vitamin C Favors control

Efficacy of diammonium glycyrrhizinate combined with vitamin C for treating hospitalized COVID-19 patients: a retrospective, observational stud

Tan et al., QJM, doi:10.1093/qjmed/hcab184
Jul 2021  
  Source   PDF   All   Meta
Vitamin C for COVID-19
7th treatment shown to reduce risk in September 2020
*, now known with p = 0.000000098 from 67 studies, recognized in 10 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
PSM retrospective 207 hospitalized patients in China, 46 treated with diammonium glycyrrhizinate and vitamin C, showing lower risk of ARDS with treatment.
This is the 31st of 67 COVID-19 controlled studies for vitamin C, which collectively show efficacy with p=0.000000098 (1 in 10 million). 18 studies are RCTs, which show efficacy with p=0.00088.
risk of death/intubation, 24.5% lower, RR 0.75, p = 0.74, treatment 1 of 46 (2.2%), control 14 of 115 (12.2%), NNT 10.0, odds ratio converted to relative risk, primary outcome.
risk of ARDS, 73.3% lower, RR 0.27, p = 0.002, treatment 7 of 46 (15.2%), control 41 of 115 (35.7%), NNT 4.9, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tan et al., 26 Jul 2021, retrospective, China, peer-reviewed, 7 authors, this trial uses multiple treatments in the treatment arm (combined with diammonium glycyrrhizinate) - results of individual treatments may vary.
This PaperVitamin CAll
Efficacy of diammonium glycyrrhizinate combined with vitamin C for treating hospitalized 2 COVID-19 patients: a retrospective, observational study 3 4
Ruoming Tan, Xiaogang Xiang, Wei Chen, Zhitao Yang, Weiguo Hu, Hongping Qu, Liu
Aims: To observe the effect of combination treatment of giammonium glycyrrhizinate and vitamin 36 C (DV)on the prognoses of patients with COVID-19. 37 Methods: This retrospective observational study recruited 207 COVID-19 patients from Tongji 38 Hospital,patients were assigned to DV and non-DV groups on the basis of the DV treatment. To 39 make the results more credible, a propensity-score matching (PSM) approach was adopted at a 1:3 40 ratio to determine the participants. Logistic analysis was used to assess the effect of DV therapy in 41 the progress of COVID-19. 42 Results: In the DV group, the new onset incidence rate of acute respiratory distress syndrome 43 (ARDS) after admission was clearly lower than that in the non-DV group (DV vs non-DV groups, 44 15.2% vs 35.7%; P=0.002). Compared with the non-DV group, the DV group showed fewer new 45 onset of complications (such as ARDS, acute liver injury and acute myocardial injury) (DV vs non-46 DV groups,19.6% vs 46.1%; P=0.000). Moreover, DG+VC may help to recover the count of NK 47 cells and decrease the level of sIL-2R. 48 Conclusions: DG+VC might be a promising candidate for preventing the deterioration of COVID-49 19 patients, which is worthy to be studied in large and perspective cohort. 50
Authors' contributions 300 LJL and HPQ contributed to study concept and design. RMT and XGX contributed to the literature
Biancatelli, Mmarik, The antiviral properties of vitamin C, Expert Rev 333 Anti Infect Ther
Chen, Hu, Hood, Zhang, Zhang et al., A Novel Combination of Vitamin C, 376 Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response 377 Associated with Coronavirus Infections: A Perspective from System Biology Analysis, Nutrients
Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical 365 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive 366 study, Lancet
Chiscano-Camon, Ruiz-Rodriguez, Ruiz-Sanmartin, Oferrer, Vitamin C levels 368 in patients with SARS-CoV-2-associated acute respiratory distress syndrome, Crit Care
Cvergoten, Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection 327 and the associated respiratory syndrome?, Pharmacol Ther
Ding, Deng, Ding, Ye, Shuang, Glycyrrhetinic acid and its derivatives as 373 potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients, J Med
Du, Liang, Yang, Wang, Cao et al., SARS-CoV-2 infection complicated 362 by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) 363 be beneficial?, Autoimmun Rev
Force, Ranieri, Rubenfeld, Thompson, Ferguson et al., Acute respiratory distress syndrome: the Berlin Definition, JAMA
Gabarre, Dumas, Dupont, Darmon, Ezafrani, Acute kidney injury in 348 critically ill patients with COVID-19, Intensive Care Med
Hiedra, Lo, Elbashabsheh, Gul, Wright et al., The use of IV vitamin 371 C for patients with COVID-19: a case series, Expert Rev Anti Infect Ther
Holford, Carr, Jovic, Ali, Whitaker et al., Vitamin C-An Adjunctive
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 320 2019 novel coronavirus in Wuhan, China, Lancet
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 343 2019 novel coronavirus in Wuhan, China, Lancet
Kwo, Smlim, ACG Clinical Guideline: Evaluation of Abnormal Liver 341 Chemistries, Am J Gastroenterol
Li, Sun, Liu, Natural products in licorice for the therapy of liver diseases: Progress and 329 future opportunities, Pharmacol Res
Li, Wu, Li, Liang, Kpchen, Integrative pharmacological mechanism of vitamin 322 C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses, Bioinform
Luo, Liu, Li, Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic 325 agent for COVID-19, Int J Antimicrob Agents
Riva, Yuan, Yin, Martin-Sancho, Matsunaga et al., SARS-CoV-2 was associated with organ dysfunction such as ARDS, acute heart injury, acute 238 kidney injury, shock and acute liver injury,significant cases progressed rapidly to severe forms 239
Singer, Deutschman, Seymour, Shankar-Hari, Annane et al., The 345 Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), JAMA
Wu, Chen, Cai, Xia, Zhou et al., Risk Factors Associated With Acute 350 Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia 351 in Wuhan, China, JAMA Intern Med
Zhang, Rao, Li, Zhu, Liu et al., Harm of IV High-Dose 337 Vitamin C Therapy in Adult Patients: A Scoping Review, Ann Intensive Care
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop